Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JEYCT
ADC Name
B5-MTX
Synonyms
B5MTX; B5 MTX
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
Drug-to-Antibody Ratio
42.6
Antibody Name
Anti-DLA-DR mAb B5
  Antibody Info 
Antigen Name
Leukocyte surface antigen CD47
  Antigen Info 
Payload Name
Methotrexate
  Payload Info 
Therapeutic Target
Dihydrofolate reductase (DHFR)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
5
nM
CLBL-1 cells
Canine lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 5.00 nM Positive DLA-DR expression (DLA-DR+++/++)
Method Description
For in vitro cytotoxicity assays, 1.25 x 105 cells were seeded on a 24-well plate. The cells were preincubated for 2 h with 20 M ZVAD. Then, 2 ug/mL of B5 or B5-MTX were added to the cells.
In Vitro Model Canine lymphoma CLBL-1 cells CVCL_L322
References
Ref 1 An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma. Cancers (Basel). 2019 Sep 26;11(10):1438. doi: 10.3390/cancers11101438.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.